Patents by Inventor Danilo Casimiro
Danilo Casimiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148651Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: ApplicationFiled: August 30, 2023Publication date: May 9, 2024Inventors: Danilo CASIMIRO, Sudha CHIVUKULA, Kirill KALNIN, Timothy PLITNIK, Timothy TIBBITTS, Angela Lynne BEAULIEU, Frank DEROSA, Anusha DIAS, Rebecca L. GOLDMAN, Hardip Rajeshbhai GOPANI, Shrirang KARVE, Asad KHANMOHAMMED, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish L. SARODE, Khang Anh TRAN
-
Publication number: 20240091154Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: ApplicationFiled: November 7, 2023Publication date: March 21, 2024Inventors: Danilo CASIMIRO, Sudha CHIVUKULA, Kirill KALNIN, Timothy PLITNIK, Timothy TIBBITTS, Angela Lynne BEAULIEU, Frank DEROSA, Anusha DIAS, Rebecca L. GOLDMAN, Hardip Rajeshbhai GOPANI, Shrirang KARVE, Asad KHANMOHAMMED, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish L. SARODE, Khang Anh TRAN
-
Publication number: 20240016918Abstract: Provided are novel vaccines for prophylactic treatment of SARS-CoV-2 infections and COVID-19 and methods of making the vaccines.Type: ApplicationFiled: August 23, 2021Publication date: January 18, 2024Applicant: SANOFI PASTEUR INC.Inventors: Natalie ANOSOVA, Salvador Fernando AUSAR, Catherine BERRY, Florence BOUDET, Danilo CASIMIRO, Roman M. CHICZ, Gustavo DAYAN, Guy DE BRUYN, Carlos DIAZGRANADOS, Tong-Ming FU, Marie GARINOT, Lorry GRADY, Sanjay GURUNATHAN, Kirill KALNIN, Nikolai KHRAMTSOV, Valérie LECOUTURIER, Nausheen RAHMAN, Sophie RUIZ, Stephen SAVARINO, Saranya SRIDHAR, Indresh K. SRIVASTAVA, James TARTAGLIA, Timothy TIBBITTS
-
Patent number: 11771653Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: GrantFiled: June 30, 2022Date of Patent: October 3, 2023Assignee: SANOFIInventors: Danilo Casimiro, Sudha Chivukula, Kirill Kalnin, Timothy Plitnik, Timothy Tibbitts, Frank Derosa, Anusha Dias, Rebecca L. Goldman, Hardip Rajeshbhai Gopani, Shrirang Karve, Asad Khanmohammed, Priyal Patel
-
Patent number: 11771652Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: GrantFiled: November 5, 2021Date of Patent: October 3, 2023Assignee: SANOFIInventors: Danilo Casimiro, Sudha Chivukula, Kirill Kalnin, Timothy Plitnik, Timothy Tibbitts, Frank Derosa, Anusha Dias, Rebecca L. Goldman, Hardip Rajeshbhai Gopani, Shrirang Karve, Asad Khanmohammed, Priyal Patel
-
Publication number: 20230302112Abstract: The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.Type: ApplicationFiled: November 4, 2022Publication date: September 28, 2023Inventors: Danilo Casimiro, Hardip Rajeshbhai Gopani, Joshua DiNapoli, Linong Zhang, Mark Parrington, Rebecca L. Goldman, Sudha Chivukula, William Scott Gallichan
-
Publication number: 20230270834Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: ApplicationFiled: March 16, 2023Publication date: August 31, 2023Inventors: Dominick Laddy, Danilo Casimiro, Thomas Evans, Megan Fitzpatrick Forrest, Nathalie Cadieux
-
Patent number: 11638749Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: GrantFiled: October 15, 2018Date of Patent: May 2, 2023Assignee: International AIDS Vaccine Initiative, Inc.Inventors: Dominick Laddy, Danilo Casimiro, Thomas Evans, Megan Fitzpatrick Forrest, Nathalie Cadieux
-
Publication number: 20220378701Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: ApplicationFiled: June 30, 2022Publication date: December 1, 2022Inventors: Danilo CASIMIRO, Sudha CHIVUKULA, Kirill KALNIN, Timothy PLITNIK, Timothy TIBBITTS, Angela Lynne BEAULIEU, Frank DEROSA, Anusha DIAS, Rebecca L. GOLDMAN, Hardip Rajeshbhai GOPANI, Shrirang KARVE, Asad KHANMOHAMMED, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish L. SARODE, Khang Anh TRAN
-
Publication number: 20220347100Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: ApplicationFiled: June 30, 2022Publication date: November 3, 2022Inventors: Danilo CASIMIRO, Sudha CHIVUKULA, Kirill KALNIN, Timothy PLITNIK, Timothy TIBBITTS, Angela Lynne BEAULIEU, Frank DEROSA, Anusha DIAS, Rebecca L. GOLDMAN, Hardip Rajeshbhai GOPANI, Shrirang KARVE, Asad KHANMOHAMMED, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish L. SARODE, Khang Anh TRAN
-
Publication number: 20220142923Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Inventors: Danilo CASIMIRO, Sudha CHIVUKULA, Kirill KALNIN, Timothy PLITNIK, Timothy TIBBITTS, Angela Lynne BEAULIEU, Frank DEROSA, Anusha DIAS, Rebecca L. GOLDMAN, Hardip Rajeshbhai GOPANI, Shrirang KARVE, Asad KHANMOHAMMED, Natalia VARGAS MONTOYA, Priyal PATEL, Ashish L. SARODE, Khang Anh TRAN
-
Publication number: 20200282038Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.Type: ApplicationFiled: October 15, 2018Publication date: September 10, 2020Inventors: Dominick Laddy, Danilo Casimiro, Thomas Evans, Megan Fitzpatrick, Nathalie Cadieux
-
Publication number: 20160040124Abstract: The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and/or maintained in reduced phosphate serum-free insect cell media.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: James M. Wagner, Shyamsundar Subramanian, David Pajerowski, Danilo Casimiro, John Balliet (DECEASED), Jessica Flynn, Jennifer Galli, Patrick McHugh, Dawn Hall, Christopher Daniels, Jennifer Girard
-
Publication number: 20150307850Abstract: The present invention relates to a cytomegalovirus (CMV) which has been recombinantly altered to express a heterologous polypeptide and to allow for external control of viral replication. The heterologous polypeptide may be a polypeptide of interest such as an antigen, antibody or immune modulator. The CMV vectors of the invention are replication defective, or chemically controllable replication capable, or replication competent. The present invention also relates to uses of the CMV vectors such as inducing an immune response to an antigen or expressing an antibody or immune modulator in vivo. Compositions comprising the CMV expressing the heterologous polypeptide are also encompassed by the present invention.Type: ApplicationFiled: December 4, 2013Publication date: October 29, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Tong-Ming Fu, Dai Wang, Danilo Casimiro, Daniel C. Freed, Fengsheng Li
-
Publication number: 20120177684Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.Type: ApplicationFiled: March 19, 2012Publication date: July 12, 2012Inventors: Janine T. Bryan, Michelle K. Brownlow, Li Shi, Danilo Casimiro, William L. McClements, Brian K. Meyer, Binghua Hu
-
Publication number: 20100189744Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.Type: ApplicationFiled: March 26, 2010Publication date: July 29, 2010Inventors: Janine T. Bryan, Michelle K. Brownlow, Li Shi, Danilo Casimiro, William L. McClements
-
Patent number: 7709010Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.Type: GrantFiled: March 6, 2008Date of Patent: May 4, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Janine T. Bryan, Michelle K. Brownlow, Li Shi, Danilo Casimiro, William L. McClements, Brian K. Meyer, Binghua Hu
-
Publication number: 20080248062Abstract: The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection.Type: ApplicationFiled: March 6, 2008Publication date: October 9, 2008Inventors: Janine T. Bryan, Michelle K. Brownlow, Li Shi, Danilo Casimiro, William L. McClements, Brian K. Meyer, Binghua Hu
-
Publication number: 20080063656Abstract: Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a polypeptide(s) (e.g, a protein or antigen) of interest. Adenoviral infection is quite common in the general population, and a large percentage of people have neutralizing antibodies to the more prevalent adenoviral serotypes. Such pre-existing anti-adenoviral immunity can dampen or possibly abrogate the effectiveness of this virus for the delivery and expression of heterologous proteins or antigens. The method taught herein functions to offset pre-existing immunity through the delivery of the protein or antigen by a cocktail of at least two adenoviral serotypes. Utilizing a composition of at least two adenoviral serotypes in this manner has been found to increase the effectiveness of adenoviral administration.Type: ApplicationFiled: August 5, 2005Publication date: March 13, 2008Inventors: Emilio Emini, John Shiver, Danilo Casimiro, Andrew Bett
-
Publication number: 20070077257Abstract: First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.Type: ApplicationFiled: November 27, 2006Publication date: April 5, 2007Inventors: Emilio Emini, Rima Youil, Andrew Bett, Ling Chen, David Kaslow, John Shiver, Timothy Toner, Danilo Casimiro